<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04232566</url>
  </required_header>
  <id_info>
    <org_study_id>18-004615</org_study_id>
    <nct_id>NCT04232566</nct_id>
  </id_info>
  <brief_title>Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity- AIM 2</brief_title>
  <official_title>Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity- AIM 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity is characterized by low-grade, chronic inflammation of adipose tissue (AT). This
      study is being done to better understand the relationship between inflammation in your AT,
      abnormal deposition of fat around your liver and how this affects its appearance and function
      and ultimately insulin resistance.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>one group of obese, non diabetic subjects will be followed for 1 yr after bariatric surgery</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Liver fibrosis</measure>
    <time_frame>comparing elastography data at 12 months post surgery vs baseline</time_frame>
    <description>evaluate the change in liver fibrosis before and after surgical intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adipose tissue inflammation</measure>
    <time_frame>comparing fat tissue inflammation at 0, 6 and 12 months post surgery</time_frame>
    <description>on adipose tissue we will assess markers of inflammation by mRNA levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>weight loss-fibrosis</measure>
    <time_frame>12 months vs baseline</time_frame>
    <description>correlation between weight loss and fibrosis of the liver changes</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Obesity, Morbid</condition>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <condition>Chronic Inflammation</condition>
  <arm_group>
    <arm_group_label>Weight loss post surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gastric bypass surgery will be followed by weight loss. Liver fibrosis by elastography will be determined before and after surgery in parallel w weight loss</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bariatric surgery</intervention_name>
    <description>we will evaluate liver improvement by elastography before and after gastric bypass surgery. Pt will be followed at 0,3,6,12 months.</description>
    <arm_group_label>Weight loss post surgery</arm_group_label>
    <other_name>Roux en Y gastric bypass, sleeve gastrectomy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed AUROC F&gt;2 liver fibrosis

          -  Age 30-70 years

          -  Male or Female

          -  BMI greater than 40 kg/m^2

        Exclusion Criteria:

          -  Autoimmune diseases

          -  Hepatitis B or C positive

          -  Glucocorticoid therapy

          -  Heavy alcohol use

          -  Active smoking history
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Anna O De Filippis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Emily Branch, BSc</last_name>
      <phone>480-301-9392</phone>
      <email>branch.emily@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Elena De Filippis, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 2, 2019</study_first_submitted>
  <study_first_submitted_qc>January 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Elena Anna (Eleanna) De Filippis, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>nash</keyword>
  <keyword>adipose tissue inflammation</keyword>
  <keyword>insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

